Dr Martens, a renowned boot manufacturer, anticipates a significant financial impact from US tariffs this year. The company, famous for its iconic footwear, now predominantly produces its shoes in Vietnam, facing increased import duties due to the ongoing trade war initiated by US President Donald Trump.
Having shifted its production away from China, which previously accounted for half of its manufacturing, Dr Martens is now focusing on reducing US import tariffs. Despite the expected negative effect of tariffs on profits, the company maintains its full-year profit forecast range between £53 million and £60 million.
Following this announcement, Dr Martens’ stock experienced a sharp decline of over 10% during early trading. The company, known for its classic yellow-stitched boots, plans to offset the additional tariff costs starting from the next fiscal year onwards through cost management strategies and adjustments to its US pricing.
While reporting a reduced loss of £11 million in the first half of the year compared to the previous year, Dr Martens saw a slight increase in sales to £327.3 million. The CEO, Ije Nwokorie, expressed confidence in the brand’s strength and highlighted the positive response to new product launches.
Investment director Russ Mould commented on Dr Martens’ progress, noting improvements in product pricing and sales in the Americas region. Despite positive signs in the half-year results, market response to the company’s performance was subdued, with a decline in share prices reflecting investor disappointment.